Aldosterone induces cardiac remodeling in cardiovascular diseases by stimulating the proliferation, production and secretion of collagen in fibroblasts. It also stimulates vascular smooth muscle cells to produce and secrete adrenomedullin (ADM), which has a cytoprotective effect against cardiovascular damage. We examined the effect of aldosterone on ADM production and secretion in rat cardiac fibroblasts, and the effect of ADM on aldosterone-stimulated fibroblast proliferation to observe the interaction between endogenous ADM and aldosterone. We detected ADM produced and secreted from cultured cardiac fibroblasts and the intracellular cAMP level by radioimmunoassay; evaluated cell proliferation by the level of [ Our results showed that aldosterone-stimulated secretion of ADM and its mRNA expression were concentrationdependent, which could be inhibited by the specific antagonist of mineralocorticoid receptor, spironolactone. In contrast, ADM inhibited aldosterone-induced fibroblast proliferation and ERK activity. Treatment with ADM 24-50 (a new antagonist of specific ADM receptors) and calcitonin gene-related peptide (CGRP) (the antagonist of CGRP receptor type 1), to attenuate the action of endogenous ADM, reinforced the aldosterone-induced proliferation and inhibited the intracellular cAMP production stimulated by aldosterone. Thiorphan, an inhibitor of ADM degradation, inhibited the [ 3 H]-thymine incorporation and reinforced the intracellular cAMP level induced by aldosterone. We reach the conclusion that aldosterone stimulates rat cardiac fibroblasts to produce and secrete ADM, which in turn regulates the proliferationinduced effects of aldosterone in these cells.
Introduction
The renin-angiotensin-aldosterone system (RAAS), important in regulating the structure and function of the heart and vascular wall, plays a central role in cardiovascular adaptive processes [1] . RAAS is also located in cardiovascular tissues, acting in a paracrine/autocrine manner [2] . Aldosterone is secreted from not only the zona glomerulosa of the adrenal cortex but also from such extraadrenal tissues as the brain and cardiovascular tissues [1] . Currently, many studies have shown that significant mRNA levels of 11 hydroxylase and CYP11B2, the terminal enzymes of corticosterone and aldosterone synthesis, have been detected in cardiovascular tissues, and higher aldosterone levels are present in cardiovascular tissues than in plasma [1, 3] . In addition, normal cardiac (atrial and ventricular) tissue contains abundant, specific, high-affinity receptors-mineralocorticoid receptors (MR) -for aldosterone, which suggests a whole pathway for aldosterone in the cardiovascular system [1] . The heart is not only a major production site for aldosterone but also the target organ of its biological actions [2, 4] . Aldosterone, important in cardiac physiology and pathophysiology, induces hypertrophy in cardiac myocytes and the proliferation, synthesis and secretion of collagen among fibroblasts and vascular smooth muscle cells (VSMCs) in cardiac fibrosis, hypertension, and atherosclerosis [2, 5] . The administration of specific inhibitors of aldosterone is an important therapeutic strategy to antagonize fibrosis in cardiovascular tissues in these diseases [6] . Two thirds of cardiac cells are nonmyocytes, most of which are fibroblasts [5] . Cardiac fibroblasts are major target cells for aldosterone action in the heart [5, 7] . Growing evidence suggests that cardiac fibroblasts have an important paracrine/autocrine action in regulating cardiac structure and function under physiological or pathophysiological conditions by secreting bioactive factors such as nitric oxide (NO), bioactive peptides, growth factors and cytokines [8, 9] .
Human adrenomedullin (ADM) consists of 52 amino acids (50 amino acids for rat) and has a cyclic ring structure formed by an intramolecular disulfide bridge and a carboxyterminal amidated residue, which has multiple functional properties. ADM inhibits VSMC proliferation and cardiomyocyte hypertrophy, induces vasodilatation, hypotension and natriuresis, and plays an important role in cardiovascular protection during hypertension, heart failure and ischemic injury [10] . ADM is expressed in the heart, lung, kidney, intestine and vessels [10] . Besides myocytes, cardiac fibroblasts synthesize and secrete ADM in a paracrine/autocrine manner and are major sources of ADM in cardiac tissues [11] . Uemura et al. [12] reported that aldosterone's stimulation of preproADM gene expression in cultured VSMCs was concentration-dependent and showed a concomitant increase in ADM secretion from the cells. As well, spironolactone, an inhibitor of aldosterone, significantly inhibited aldosterone-induced ADM secretion. However, it is not clear how aldosterone-induced secretion of endogenous ADM from cardiac fibroblasts affects aldosterone action in the heart [12, 13] . To examine the possible paracrine/autocrine interaction between aldosterone and ADM, we studied the effect of aldosterone on ADM production and its mRNA expression in rat cardiac fibroblasts and the effect of ADM on aldosterone-induced fibroblast proliferation.
Materials and methods

Materials
Male Wistar rats (1-3 days old) were purchased from the Animal Center, Health Science Center, Peking University (Beijing, China). All experiment procedures were performed in accordance with the Guidelines of Animal Experiments from the Committee of Medical Ethics, National Health Department of China. Rat ADM (1-50), ADM , calcitonin gene-related peptide (CGRP) ) . The sequences of oligonucleotide primers were ADM-S, 5V-CTCGACACTTCCTCGCAGTT, and ADM-A, 5V-GCTGGAGCTGAGTGTGTCTG, used for the amplification of ADM cDNA, and h-actin-S, 5V-CATCCGTAAAGACCTCTATGCCAAC-3V and h-actin-A, 5V-CAAAGAAAGGGTGTAAAACGCAGC-3V, for the amplification of h-actin for calibration of sample loading. Other chemicals and reagents were of analytical grade.
Culture and identification of cardiac fibroblasts
Cultured cardiac fibroblasts were isolated from cardiac ventricles of neonatal Wistar rats as described [11] , with some modification. After the minced ventricles were digested with 0.12% trypsin and 0.03% collagenase, the cells were collected and plated for 30 min at 37 8C to allow fibroblasts to attach to the 10-cm cell culture plates in 10 ml of Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS). Then the medium was decanted and the cardiac fibroblasts were cultured in 10 ml of DMEM with 10% FBS at 37 8C in a 95% air/5% CO 2 humidified atmosphere to confluence. Cells were then subcultured: cells at the third passage were divided into 24-well culture plates at a density of 10 5 cells/well and grown to a confluency of about 70% in 1.0 ml/well of DMEM supplemented with 10% FBS. To achieve quiescence, the cells were incubated with serum-free medium for 24 h. After being starved, the cells were treated with the peptides and/or agents described in fresh serum-free medium. Immunocytochemical analysis was performed as previously described [14] by indirect immunoperoxidase labeling with an avidin-biotin peroxidase (ABC-HRP) immunostaining kit (Vector, Burlingame, CA, USA), with some modification. Briefly, cultured cardiac fibroblasts were fixed with 10% formaldehyde. After blocking the endogenous peroxidase with 0.6% hydrogen peroxide in methanol, the slides were incubated with Tris-buffered saline (TBS) containing 0.1% Triton X-100, 3% normal rabbit serum, and 1% dry milk to reduce the nonspecific background, then with primary antibodies at room temperature for 24 h. Immunoreactive sites were revealed by incubating the cardiac fibroblasts with 0.05% (wt/vol) diaminobenzidine (DAB) and 0.003% (vol/vol) H 2 O 2 in 50 mmol/l Tris-HCl (pH 7.6) for 5 min. Sections were then counterstained with hematoxylin before being dehydrated in ethanol. Specificity of the antibody was confirmed by substitution with non-immune mice serum or absorption test. As shown in Fig. 1 , there was positive staining for vimentin but negative staining for von Willebrand factor (factor VIII) and a-smooth muscle actin in all cardiac fibroblasts, which indicates little contamination of vascular endothelial cells or smooth muscle cells in the fibroblast culture.
Viability of cardiac fibroblasts
Specimens were soaked in 0.1% trypan blue solution in phosphate-buffered saline (PBS) [15] and incubated at 37 8C for 2 min. After several washes with warm PBS, specimens were reincubated at 37 8C for 30 min in DMEM containing 10% FBS. Viable cells appeared lucid and dead cells blue. After one more wash with warm PBS, the specimens were evaluated under a standard inverted light microscope for degree of staining. The ratio of viable cells was calculated as viable cells to total cells.
Measurement of immunoreactive ADM (ir-ADM) in culture media and characteristics of secreted ADM
Culture media were collected after 12 and 24 h. The samples were acidified with acetic acid to a final concentration of 1.0 mol/l and heated at 100 8C for 10 min to inactivate proteases. The collected media were loaded onto a Sep-Pak C 18 cartridge (Waters, MA, USA) and pre-equilibrated with 0.5 mmol/l acetic acid; the adsorbed material was eluted with 4 ml of 50% CH 3 CN containing 0.1% trifluoroacetic acid (TFA). After the samples were lyophilized, the residue was dissolved in radioimmunoassay buffer and assayed according to the manufacturer's instructions (Phoenix Pharmaceutical). The IC 50 of ADM assay was 25.6 pg/tube and the reactivity with rat ADM 100%. No cross-reactivity with rat proADM N-terminal 20 peptide (PAMP), amylin or endothelin was found. The content of secreted ir-ADM was calculated and expressed as fmol/10 5 cells. The within-and betweenassay coefficients of variation for the ir-ADM assay were both less than 10%.
The culture media was analyzed by reverse-phase high performance liquid chromatography (HPLC) [11] to examine the molecular forms of ir-ADM: samples were pumped onto a column of TSK ODS 120A (4.6 mmÂ25 cm; Tosoh, Tokyo, Japan) equilibrated with a linear gradient of 0-60% acetonitrile in 0.1% TFA, at a flow rate of 2 ml/min, and the ir-ADM in each fraction was measured by radioimmunoassay. The recovery of ir-ADM in the HPLC analysis was more than 80%.
RT-PCR studies
The expression of preproADM mRNA was assessed by reverse-transcriptase polymerase chain reaction (RT-PCR) as described [16] , with some modification. Isolated total RNA was quantified by use of an ultraviolet (UV) spectrophotometer (DU-640, Beckman, USA) and loaded 2-5 Ag onto agarose gels containing 1.2% formaldehyde to prove no contamination of genomic DNA. Reverse transcription to cDNA was accomplished by priming 2-Ag total RNA samples with MMLV and oligo(dT) 15 primer. Products were then used for the following PCR amplification: the PCR reaction mixture in 25 Al containing 2.5 mmol/l dNTP 1 Al, 10Â PCR buffer (20 mmol/l MgCl 2 , 500 mmol/l KCl, 1.5 mol/l Tris-HCl, pH 8.7) 2.5 Al, cDNA 2 Al, 200 nmol/l of the appropriate ADM paired primers and 1.25 units of Taq DNA polymerase. The PCR cycles used were 94 8C for 30 s, 57 8C for 30 s and 72 8C for 40 s, for 30 cycles, then 74 8C for 5 min. As an internal control for each PCR reaction, h-actin mRNA was also amplified with each sample. A total of 200 nmol/l of hactin primers and cDNA 2 Al were amplified under the same reaction conditions. All PCR products were loaded onto a 1.5% agarose-Tris-acetate-EDTA gel before electrophoresis and then visualized on ethidium bromide staining. The UV illumination photos underwent computerized densitometric analysis. Final results were expressed as the ratio of ADM PCR product (446 bp) to h-actin PCR product (291 bp) for each sample. The amplified ADM cDNA and h-actin were confirmed by digestion of the PCR products with restriction enzyme MSP I. All experiments were repeated three times.
Measurement of [ 3 H]-TdR incorporation
The effect of aldosterone on proliferation of cardiac fibroblasts was evaluated by the rates of DNA synthesis, incorporating [ 3 H]-TdR into cardiac fibroblasts as described [17] , with some modification. Cultured serumstarved fibroblasts were divided into the following groups: (1) control (fibroblasts cultured in culture medium alone); (2) ADM (10 À7 mol/l), ADM 24-50 (10 À6 mol/l; the antagonist for ADM receptors [18] ), CGRP (10 À6 mol/l; the antagonist for CGRP type 1 receptor [10] ) and thiorphan (20 nmol/l, the specific inhibitor of neutral endopeptidase ([E.C.3.4.24.11], NEP), the major enzyme in ADM degradation [19] ) alone, respectively; (3) aldosterone (10 À8 , 10 À7 and 10 À6 mol/l added into the medium); (4) aldosterone (10 À6 mol/l) plus ADM (10 À9 ,10 À8 and 10 À7 mol/l, respectively); and (5) aldosterone (10 À6 mol/l) plus inhibitor (10 À6 mol/l ADM 24-50 , 10 À6 mol/l CGRP or 20 nmol/l thiorphan, respectively, added 20 min before aldosterone). The fibroblasts were exposed to 1 ACi/ ml [ 3 H]-TdR 12 h after the beginning of the incubation, which lasted 24 h and was terminated by washing with cold PBS twice, then underwent incubation with 10% trichloroacetic acid at 4 8C for 20 min. After cell residues were rinsed with 95% ethanol, the dried materials were solubilized in 0.5 N NaOH for 2 h. Radioactivity in the solubilized samples was determined with use of a liquid scintillation counter (LS6500, Beckman). The results are expressed as percentages relative to the mean cpm/10 5 cell of the control for each experiment.
Assay for cyclic adenosine monophosphate (cAMP)
The cAMP was detected as described [16] , with some modification. The rat cardiac fibroblasts were plated in sixwell plates. When confluent, DMEM medium was replaced with fresh medium supplemented with 2 mmol/l IBMX. Then cells were exposed to 10 À6 mol/l aldosterone in the absence or presence of different inhibitors (10 À6 mol/l ADM 24-50 , 10 À6 mol/l CGRP or 20 nmol/l thiorphan, respectively), and incubated for 4 and 12 h, respectively. The incubation was terminated by removing the medium and washing with cold PBS twice. The harvested fibroblasts were resuspended in 1 mol/l acetic acid, boiled for 5 min, and centrifuged at 7,200Âg for 3 min to remove cell debris. cAMP content in the supernatant was assayed by using the cAMP RIA kit.
Assay of ERK activity
Activity of ERK, a member of the mitogen-activated protein kinase (MAPK) family, was determined by monitoring the phosphorylation of MBP in the presence of [g-32 P] ATP as described [20] , with some modification. After incubation for 30 min, the control fibroblasts and those exposed to ADM (10 À7 mol/l) alone and 10 À6 mol/l aldosterone in the presence or absence of 10 À9 -10 À7 mol/l ADM were rinsed with ice-cold PBS containing 1 mmol/l sodium orthovanadate (a nonspecific tyrosine phosphatase inhibitor). The culture plates were frozen quickly in liquid nitrogen after the addition of 300 Al of lysis buffer [in mmol/l: 20 HEPES, 80 h-glycerophosphate, 10 EGTA, 2 EDTA, 2 dithiothreitol, 0.01 orthovanadate, 1 benzamidine, 1 phenylmethylsulfonyl fluoride and 0.5% Triton X-100 along with a cocktail of protease inhibitors (leupeptin, aprotinin, antipain, soy trypsin inhibitor, pepstatin A, each at a concentration of 10 Ag/ml)]. The culture plates were thawed on ice, scraped, lysate sonicated, and centrifuged at 16,000Âg at 4 8C for 20 min, and the protein concentration in supernatants was determined by staining with Coomassie blue. Equal amounts of proteins (50 Ag) from the resulting supernatants were immunoprecipitated with rabbit polyclonal anti-ERK antibody (2 Ag) for 2 h at 4 8C, then 50 Al of protein A Sepharose (50% vol/vol) was added. The immune complexes were further incubated with anti-mouse IgG-agarose beads for 30 min under the same conditions and washed with lysis buffer six times. The immune complexes were incubated with assay buffer (in mmol/l: 50 h-glycerol phosphate, 1.5 EGTA, 0.1 Na 3 VO 4 , 1 DTT, 200 calmidazolium, 4 protein kinase A inhibitor, 20 MgCl 2 , 0.2 ATP-Na 2 , 1 mg/ml myelin basic protein and 2.5 ACi of [g-32 P] ATP per assay). Reactions lasted 15 min at 30 8C and were terminated by spotting the reaction mixture on P-81 Whatman phosphocellulose filter paper squares (2.5Â2.5 cm 2 ). Filter papers were subsequently washed four times with 0.85% H 3 PO 4 , four times with water and once with acetone in the final wash. Papers were dried and transferred to scintillation vials, cytoscint scintillation fluid was added, and radioactivity was counted. Data were calculated as cpm per milligram protein per minute.
Statistical analysis
Results are meanFS.E. Comparisons were performed with unpaired Student's t-test and one-way ANOVA, then with Student-Newman-Keuls test; a P value b0.05 was considered statistically significant.
Results
Aldosterone increased ir-ADM secretion
Aldosterone-stimulated ADM secretion from cardiac fibroblasts was concentration-dependent ( Fig. 2A) . After incubation with aldosterone (10 À8 -10 À6 mol/l), the ADM secretion was increased 15.2% ( PN0.05), 45.0% ( Pb0.01) and 90.8% ( P b0.01), respectively, at 12 h, and 19.1%~68.2% ( Pb0.05 or Pb0.01), respectively, at 24 h. As shown in Fig. 2B , when cardiac fibroblasts co-incubated with spironolactone, an antagonist for MR, the ADM secretion induced by aldosterone was decreased by 35.0% ( Pb0.01) at 12 h and 29.8% ( Pb0.01) at 24 h, compared with those incubated with 10 À6 mol/l aldosterone alone. However, incubation with spironolactone alone (10 À6 mol/ l) had no effect on fibroblast ADM secretion not only at 12 h, but also at 24 h, compared with controls (both PN0.05). Incubation of fibroblasts with thiorphan (20 nmol/l) alone increased ADM content by 8.9% ( PN0.05) at 12 h and 22.3% ( Pb0.01) at 24 h. Interestingly, co-incubation with aldosterone (10 À6 mol/l) and thiorphan increased ADM content by 27.1% and 36.4% at 12 and 24 h, respectively (both Pb0.01), compared with aldosterone treatment alone (Fig. 2C) .
The molecular form of ADM produced by fibroblasts was characterized by use of reverse phase HPLC (Fig. 3) . ir-ADM production consisted of one major and one minor peak, the major peak appearing at an elution position identical to that of synthetic rat ADM (1-50)-NH 2 , the whole active molecule of the rat ADM peptide.
Aldosterone promoted preproADM gene expression
Aldosterone stimulation of preproADM mRNA expression was concentration-dependent, with 10 À8 , 10 À7 and 10 À6 mol/l aldosterone inducing 71.6%, 131.6% and 198.8%, respectively, higher mRNA expression than that in the control (all Pb0.01) (Fig. 4) (Fig. 5) .
ADM attenuated fibroblast proliferation induced by aldosterone
À6 mol/l aldosterone was significantly increased, by 104.4% ( Pb0.01; Fig. 6 ). Co- 
Endogenous ADM inhibited aldosterone-stimulated proliferation
To study the effect of endogenous ADM induced by aldosterone on aldosterone-stimulated proliferation, treatment with thiorphan, ADM , and CGRP revealed that thiorphan inhibited the [ 3 H]-TdR incorporation in fibroblasts induced by aldosterone (10 À6 mol/l), with 24.4% ( Pb0.05) less incorporation compared with aldosterone treatment alone (Fig. 7) ; in contrast, ADM 
Effects of different inhibitors on cAMP level in cardiac fibroblasts
Treatment with 10
À6 mol/l aldosterone alone resulted in an increase in intracellular cAMP level by 33.9% ( PN0.05) at 4 h and 156.7% ( Pb0.01) at 12 h after the incubation, respectively, compared with controls ( Fig. 8) . At 4 h after the incubation, aldosterone co-incubated with all inhibitors (ADM , CGRP or thiorphan) induced no significant changes in intracellular cAMP levels when compared with aldosterone treatment alone; compared with the control, only aldosterone co-incubated with thiorphan (20 nmol/l) raised the intracellular cAMP level by 51.3% ( Pb0.05), but no significant change occurred when co-incubated with ADM (10 À6 mol/l) or CGRP 8-37 (10 À6 mol/l). At 12 h after the incubation, both ADM and CGRP decreased the intracellular cAMP level by 25.0% ( Pb0.05) and 39.8% ( Pb0.01), and thiorphan increased the cAMP level by 24.3% ( Pb0.05), respectively, compared with aldosterone treatment alone; compared with the control, aldosterone co-incubated with ADM 24-50 , CGRP or thiorphan showed increase in the intracellular cAMP level by 92.6% ( Pb0.01), 54.6% ( Pb0.05) and 219.3% ( Pb0.01), respectively.
ADM inhibited aldosterone-activated ERK activity
Treatment with 10
À6 mol/l aldosterone resulted in 7.9-fold higher ERK activity compared with the control ( Pb0.01; Fig. 9 ). However, co-incubation with ADM Fig. 7 (10 À9 , 10 À8 and 10 À7 mol/l) inhibited the aldosteronestimulated ERK activity in a concentration-dependent manner, with 56.4%, 69.2% and 78.0% lower activity, respectively (all Pb0.01), compared with aldosterone treatment alone. Incubation with 10 À7 mol/l ADM alone had no significant effect on ERK activity compared with the control (58496F4479 vs. 74080F5322 cpm/mg protein/min, PN0.05, both n=6).
Discussion
Cardiac tissues are rich in CYP11B2, the enzyme catalyzing the terminal or key step in the synthesis of aldosterone, and have a much higher aldosterone level than does plasma by approximately 17-fold, which indicates an independent system of aldosterone synthesis in the heart [1] . Aldosterone has been reported to specifically bind to MR (or high-affinity type I sites) which are diffusely distributed in rat cardiac tissues [5] . Aldosterone binds MR within cells, then translocates to the nucleus and acts as a function transcription factor by interacting with DNA regulatory elements, finally regulating genomic transcription and translation of effector proteins [4] . Aldosterone also binds distinct receptors in the plasma membrane to induce nongenomic effects by activating diverse intracellular signal pathways, including protein kinase C (PKC), inositol triphosphate (IP 3 ) and Ca 2+ [2] . Though raised levels of aldosterone synthase, aldosterone, and MR are relatively late events in the pathological progression of cardiovascular diseases such as congestive heart failure and essential hypertension, aldosterone induces systemic hypertension, left ventricular hypertrophy and nephrosclerosis [21] . It is well known that excess aldosterone plays a key role in cardiovascular remodeling and relates closely to its onset and progression [5] , and aldosterone antagonism is important in cardiovascular protection by attenuating tissue fibrosis [4] . Cardiac fibroblasts are major target cells of aldosterone in the heart [22] . During cardiac remodeling, fibroblasts proliferate, synthesize and secrete collagens, and change to a myofibroblast phenotype [5, 22] . Cardiac fibroblasts, through paracrine/autocrine actions, release many bioactive factors including ADM to maintain heart homeostasis in structure and function [8, 11] . Myocardial cells, vascular endothelial cells and VSMCs synthesize and secrete ADM [10] . ADM is secreted from cultured cells in a constitutive manner, with little intracellular storage [12] . Tomoda et al. [23] observed that in local cardiovascular tissues, fibroblasts are a major source of ADM synthesis and secretion and themselves are target cells for ADM. Previous studies demonstrated that the administration of ADM or the delivery of the ADM gene not only produced a sustained reduction of blood pressure but also attenuated cardiac and renal dysfunction in genetic and experimental hypertensive animals, which indicates that endogenous ADM possesses a cytoprotective effect against organ damage [24] , but now little is known about the interaction between endogenous ADM and aldosterone in the heart [13] .
In the present study, we evaluated the proliferation of cardiac fibroblasts by the level of [ 3 H]-TdR incorporation. Aldosterone stimulation of fibroblast proliferation and increased [ 3 H]-TdR incorporation was concentrationdependent, as was found by Neumann et al. [25] . Fibroblasts in the control group maintained low levels of ADM secretion and mRNA expression when incubated without inducers, whereas aldosterone's strong stimulation of ADM secretion and its mRNA expression was concentration-dependent, and spironolactone, the specific antagonist for MR, significantly inhibited the induction of aldosterone-stimulated ADM secretion into the medium; these results were similar to those found in VSMCs by Uemura et al. [12] . Furthermore, on co-incubation with aldosterone, ADM's inhibition of [ 3 H]-TdR incorporation was concentration-dependent. Though at the same time, fibroblasts activated by aldosterone in our study also secreted endogenous ADM from 12.8F1.7 (10 À8 mol/l aldosterone, incubated for 12 h) to 33.4F3.4 fmol/10 5 cell (10 À6 mol/l aldosterone, incubated for 24 h), namely from 1.28F0.17Â10
À11 to 3.34F0.34Â10 À11 mol/l, the endogenous ADM concentrations were so far less than those of the exogenous ADM (from 10 À9 to 10 À7 mol/l) that the endogenous ADM might yield little effect on the actions of the exogenous ADM. Two clearance pathways of ADM in tissue have been recognized: protease hydrolysis and binding to ADM clearance receptors [26] . On co-incubation with thiorphan, an inhibitor of NEP which degrades ADM, ADM content was increased, and aldosterone-induced [
3 H]-TdR incorporation was attenuated, which was probably due to the decrease in endogenous ADM degradation resulting from NEP inhibition.
ADM exerts its actions through a receptor pathway [10] , but the exact signal transduction pathways activated by ADM are uncertain [27] . Some effects of ADM result from its interaction with CGRP type 1 receptors, which are blocked by the CGRP antagonist CGRP 8-37 [11] , and other ADM effects through specific ADM receptor isotypes, which can be fully inhibited by ADM , a new found N-terminal-deleted form of rat ADM [18] . The major signal transduction pathway activated by ADM is the adenylate cyclase/cAMP system [10] . We observed that cardiac fibroblasts pre-incubated with ADM to inhibit ADM receptor isotypes significantly reinforced aldosterone-stimulated proliferation, and CGRP 8-37 also little increased the proliferative induction of aldosterone by 8.0% but with no statistical difference ( PN0.05). Romppanen et al. [28] observed that the left atrial ir-ADM levels decreased significantly after 2 h of pressure overload and plasma ir-ADM levels increased slightly in response to 4 h of arginine-vasopressin infusion, so we detected the intracellular cAMP content after the incubation for 4 and 12 h. We observed that aldosterone alone increased the cAMP at least through two ways, i.e., by itself directly [29] and induction of increase in ADM content indirectly. ADM attenuated the intracellular cAMP level stimulated by aldosterone almost as effectively as that of CGRP (with no statistical difference between the action of ADM and CGRP ), which was similar to the results of Nishikimi et al. [30] . Increase in intracellular cAMP level is involved in the inhibition of ADM in the proliferation and protein synthesis of cardiac fibroblasts [11] , and our results indicated that both specific ADM receptor isotypes and CGRP type 1 receptors possibly distribute in cardiac fibroblasts, and ADM might perform its antagonism against the aldosterone-induced proliferation not only through specific ADM receptors, but also through CGRP type 1 receptors. Increasing evidence has supported the original hypothesis of Foord and associates that calcitonin-receptorlike receptor (CRLR) with receptor-activity-modifying protein (RAMP)1 forms a CGRP type 1 receptor and CRLR with RAMP2 or RAMP3 forms an ADM preferring receptor in transfected cell lines [27] , but the distribution of CGRP type 1 receptors and specific ADM receptors in cardiac fibroblasts is still unknown. Chakravarty et al. [27] observed that the levels of ADM binding were far higher than those for CGRP in rat cardiac tissue; Coppock et al. [31] demonstrated that the Rat-2 fibroblasts expressed specific ADM receptors, but did not express CGRP receptors. Our results showed that CGRP was able to inhibit the cAMP production but had no significant effect on [ 3 H]-TdR incorporation in cardiac fibroblasts while ADM was effective in both experiments, which suggested that when ADM interacts with CGRP type 1 receptors in cardiac fibroblasts, it might induce the cAMP production and the inhibition of [ 3 H]-TdR incorporation by completely different signal transduction pathways, and the specific ADM receptors possibly play a more important role than CGRP type 1 receptors do in mediating the inhibition of ADM on fibroblast proliferation. Tsuruda et al. [14] reported that the cultured cardiac fibroblasts produced and secreted brain natriuretic peptide (BNP) to regulate the myocardial structure; Horio et al. [32] observed that cardiac fibroblasts also produced C-type natriuretic peptide (CNP) to act as an autocrine regulator against excessive cardiac fibrosis. NEP is also the major enzymatic pathway to degrade the natriuretic peptides [19] , so it is reasonable to consider that in our experiment the BNP and CNP produced by cardiac fibroblasts were also increased as ADM when thiorphan was given to inhibit the NEP. The biological effect of natriuretic peptides to inhibit cell proliferation in cardiovascular system is achieved by stimulating the guanylate cyclase A receptors to regulate intracellular cyclic guanosine monophosphate (cGMP) level but not cAMP [33] . We observed that when aldosterone was co-incubated with thiorphan, the intracellular cAMP content was 13.0% ( PN0.05) and 24.3% ( Pb0.05) higher at 4 and 12 h after the incubation, respectively, than those of aldosterone treatment alone. The inhibition of NEP must increase the ADM content to increase intracellular cAMP, which probably mediates the inhibition of the aldosterone-stimulated fibroblast proliferation. In fibroblasts, MAPK signaling mediates proliferation through the activation of tyrosine kinase-associated and G protein-coupled receptors [34] . We observed that aldosterone-activated MAPK in cardiac fibroblasts, as was previously reported by Stockand and Meszaros [34] , was inhibited by ADM being concentration-dependent. Thus, our results indicated that aldosterone stimulated cardiac fibroblasts to produce and secrete ADM, which, in turn, regulated the proliferation-induced effects of aldosterone in these cells.
Currently, the mechanism by which aldosterone stimulates ADM expression and secretion in fibroblasts is unclear. The genomic DNA of human ADM has been mapped and localized to a single locus of chromosome 11 and consists of four exons and three introns. The mature ADM peptide is coded in the fourth exon. The 5V flanking region of the ADM gene contains TATA, CAAT, CC boxes, several binding sites for activator protein-2 (AP-2) and a cAMP-regulated enhancer element [10] . The expression of the ADM gene may be subject to signaltransduction pathways, including PKC and cAMP, and regulated by many physiological or pathophysiological factors. Blood volume overloading, tachycardia, cytokines and growth factors can stimulate the transcription of ADM mRNA [10] . Factors such as angiotensin II, endothelin-1, norepinephrine, and physical stimuli (shear stress or/and stretching), which participate in cardiovascular diseases, induce the heart and vessels to synthesize and secrete ADM [28, 35] . In our study, aldosterone increased ADM secretion and the up-regulation of its mRNA in cardiac fibroblasts, which was probably the result of the activated transcription of ADM mRNA induced by aldosterone through the MR pathway. Stockand and Meszaros [34] reported that aldosterone increased rat cardiac fibroblast proliferation directly through the MR-dependent activation of Kirsten Ras (Ki-RasA) and its effector, the MAPK cascade. We also observed that aldosterone stimulated cardiac fibroblast proliferation (expressed as [ 3 H]-TdR incorporation) associated with the activation of MAPK. Coppock et al. [31] found that in Rat-2 fibroblasts, ADM acted via its receptors to increase intracellular cAMP and inhibit MAPK activation. Taken together, our results indicate that the inhibitory effect of ADM on aldosterone-stimulated cardiac fibroblast proliferation could be induced by elevating intracellular cAMP and suppressing aldosterone-activated MAPK activity.
Several studies have shown that ADM and aldosterone interact in local tissues [13] . In dispersed rat capsular and inner adrenocortical cells, ADM depressed aldosterone production through the CGRP type 1 receptor [36] . Rebuffat et al. [37] observed that in dispersed rat zona glomerulosa cells, ADM inhibited aldosterone secretion by stimulating endogenous NO synthesis. Our present study of ADM interacting with aldosterone in rat cardiac fibroblasts suggests that the cardiac actions of aldosterone are regulated by endogenous ADM in a paracrine/autocrine manner. Aldosterone stimulates the production and secretion of endogenous ADM in local cardiac tissue, which in turn antagonizes the effects of aldosterone. Our findings provide new information regarding the cardiac effects of aldosterone and mechanisms involved in the cardioprotective effects of ADM. The physiological implications of this interaction, especially under pathologic conditions, need further study for understanding the roles of ADM and aldosterone in cardiovascular diseases.
